Viracta Therapeutics to Present at the 21st Annual Needham Virtual Healthcare Conference

Rhea-AI Summary

Viracta Therapeutics, Inc. (Nasdaq: VIRX) announced its participation at the 21st Annual Needham Virtual Healthcare Conference on April 13, 2022, at 3:00 p.m. EDT. The presentation will focus on the company's precision oncology initiatives targeting virus-associated malignancies, particularly its lead product candidate, Nana-val. This all-oral therapy combines nanatinostat and valganciclovir and is currently being evaluated in multiple trials for treating Epstein-Barr virus-positive lymphomas and nasopharyngeal carcinoma. A webcast of the presentation will be available on the Viracta website.

SAN DIEGO, April 7, 2022 /PRNewswire/ -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced that company leadership is scheduled to present at the 21^st Annual Needham Virtual Healthcare Conference, on Wednesday, April 13, 2022, at 3:00 p.m. EDT.

A webcast of the presentation will be available on the Investors section of the Viracta website under "Events and Webcasts" at https://viracta.investorroom.com/events-and-webcasts. The webcast will be archived for 30 days.

About Viracta Therapeutics, Inc.

Viracta is a precision oncology company targeting virus-associated malignancies. Viracta's lead product candidate is an all-oral combination therapy of its proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir (collectively referred to as Nana-val). Nana-val is currently being evaluated in multiple ongoing clinical trials, including a pivotal, global, multicenter, open-label Phase 2 basket trial for the treatment of multiple subtypes of relapsed/refractory Epstein-Barr virus-positive (EBV⁺) lymphoma (NAVAL-1) as well as a multinational, open-label Phase 1b/2 trial for the treatment of EBV⁺ recurrent or metastatic nasopharyngeal carcinoma and other EBV⁺ solid tumors. Viracta is also pursuing the application of its inducible synthetic lethality approach in other virus-related cancers.

For additional information please visit www.viracta.com.

Investor Relations Contact:
Ashleigh Barreto
Head of Investor Relations & Corporate Communication
Viracta Therapeutics, Inc.
abarreto@viracta.com

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/viracta-therapeutics-to-present-at-the-21st-annual-needham-virtual-healthcare-conference-301520133.html

SOURCE Viracta Therapeutics, Inc.

FAQ

What is Viracta Therapeutics presenting at the Needham Virtual Healthcare Conference?

Viracta Therapeutics will present on its precision oncology initiatives targeting virus-associated malignancies, specifically its lead product candidate Nana-val.

When is Viracta's presentation at the Needham Conference?

The presentation is scheduled for April 13, 2022, at 3:00 p.m. EDT.

Where can I watch the Viracta conference presentation?

The webcast will be available on the Investors section of the Viracta website under 'Events and Webcasts'.

What is the lead product candidate of Viracta Therapeutics?

Viracta's lead product candidate is Nana-val, which combines nanatinostat and valganciclovir.

What types of cancer is Viracta targeting with Nana-val?

Nana-val is being evaluated for treating Epstein-Barr virus-positive lymphomas and nasopharyngeal carcinoma.